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Abstract
Purpose This study aimed to assess the longitudinal asso-
ciation between lifestyle factors, body mass index (BMI),
and health-related quality of life (HRQoL) among colorec-
tal cancer patients with (CRCDM+) and without diabetes
(CRCDM−).
Methods Data from a longitudinal study among CRC pa-
tients diagnosed between 2000 and 2009 were used. Clin-
ical characteristics were retrieved from the Netherlands
Cancer Registry and questionnaires were sent in 2010,
2011, and 2012 using the Patient Reported Outcomes Fol-
lowing Initial Treatment and Long term Evaluation of Sur-
vivorship (PROFILES) registry. Lifestyle (including
moderate-to-vigorous physical activity (MVPA), smoking
and alcohol use), BMI, diabetes status, and HRQoL were
assessed in the questionnaire.
Results One thousand seven hundred thirty-nine (49 %) pa-
tients responded to ≥2 questionnaires, of whom 126 CRCDM+
and 789 CRCDM− patients were included. CRCDM+ patients
had a higher BMI (29.1±4.2 vs. 26.4±3.7 kg/m2), whereas the
number of alcohol users was lower (50 vs. 70 %, p value
<0.0001) among CRCDM+ as compared to CRCDM− pa-
tients. Analyses adjusted for sociodemographic and cancer
characteristics showed that CRCDM+ patients reported statis-
tically significantly lower physical function (beta = -5.76;
SE=1.67), global QoL (beta = -4.31; SE=1.48), and more
symptoms of fatigue (beta=5.38; SE=1.95) than CRCDM−
patients. However, these effects disappeared after adjustments
for lifestyle factors and BMI which were all significant predic-
tors of HRQoL. Additional adjustment for comorbidity further
attenuated the main effect of DM on HRQoL.
Conclusions Diabetes was not independently associated with
HRQoL but deteriorated HRQoL among CRCDM+ patients
seem to be explained by an unhealthier lifestyle and other
comorbid conditions. Moreover, residual confounding cannot
be ruled out.
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Introduction
Nowadays, the number of patients with several chronic dis-
eases or comorbidity is increasing due to the increased life
expectancy and aging of the population [1]. Both cancer and
diabetes are common chronic diseases and were among the
leading causes of death worldwide in 2008, with 7.6 and 1.3
million deaths due to cancer and diabetes, respectively [2].
Among cancer patients, diabetes is one of the most frequently
observed comorbidities with a prevalence of 14 % among
colorectal cancer (CRC) patients [3]. Previous literature shows
that patients with diabetes have an increased risk to develop
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CRC [4], and that patients with both CRC and diabetes have
about a 30 % higher mortality risk [5]. Beside these poorer
prognostic outcomes, studies also indicate that patients with
both cancer and diabetes have a poorer health-related quality
of Life (HRQoL) [6–10].
Previous studies mainly reported a lower general HRQoL
[6, 9], physical function or mobility [7, 10] and vitality [9]
among cancer patients with diabetes, compared to cancer pa-
tients without diabetes. However, the majority of these studies
focused on prostate cancer patients [8, 9, 11, 12] and had a
cross-sectional study design [6, 7, 9–11]. More importantly,
only three studies adjusted their analyses for lifestyle factors
[6, 8, 10], of which two only included bodymass index (BMI)
and no other lifestyle factors such as physical activity,
smoking, or alcohol use [8, 10].
Lifestyle factors have been shown to be important predic-
tors of HRQoL among both CRC and diabetes patients. Sev-
eral studies show that an increasing number of healthy life-
style factors are associated with better HRQoL scores among
CRC patients [13–15] as well as among diabetes patients [16].
Regarding the independent effect of lifestyle factors, two lon-
gitudinal studies among CRC patients showed that physically
active (i.e., at least 150 min/week) patients reported a higher
general HRQoL as compared to patients who were insuffi-
ciently active or inactive [17, 18]. Another cross-sectional
study from the UK reported that CRC patients who are phys-
ically active and have a moderate alcohol intake reported bet-
ter functioning and lower levels of fatigue compared to those
who did not consume alcohol [13]. No significant association
between smoking and HRQoL was found [13]. In contrast,
analyses of the Women’s Health Study showed that persistent
smoking among women with breast, colorectal, and endome-
trial cancer were more likely to report poor physical function,
poor mental health, and lower role emotional function as com-
pared to non-smoking patients [19]. Among diabetes patients,
similar associations between lifestyle and HRQoL were
found. Two cross-sectional studies showed that physical ac-
tivity was positively associated, whereas BMI was negatively
associated with both physical and mental health [20, 21].
Smoking was less often studied, but a large study (n=16,
428) from the USA showed that patients who were not
smoking were less likely to report a poor or fair health
(OR=0.71; 95 % CI 0.56–0.89) [16].
As CRC patients with diabetes (CRCDM+) are expected to
have a poorer lifestyle than CRC patients without diabetes
(CRCDM−), these poorer lifestyle behaviors might explain
the poorer HRQoL found among CRCDM+ vs. CRCDM−
patients [6–10]. Moreover, prospective studies on differences
in HRQoL between CRCDM+ and CRCDM− patients are
missing. Therefore, this study aims to assess differences be-
tween CRCDM+ and CRCDM− patients in (1) lifestyle, (2)
HRQoL measured prospectively, and (3) to assess whether
lifestyle factors explain the differences in HRQoL between
CRCDM+ and CRCDM− patients. As the main focus of this
study was to assess the effect of individual lifestyle factors on
HRQoL longitudinally, we confined the analyses to the inde-
pendent lifestyle effects and did not include a composite life-
style score. We hypothesize that CRCDM+ patients have a
poorer lifestyle and lower HRQoL as compared to CRCDM
− patients.
Methods
Setting and study population
Data from a large population-based study among CRC pa-
tients were used. All CRC patients diagnosed between Janu-
ary 2000 and June 2009 were sampled from the southern area
of the Netherlands Cancer Registry (NCR). The NCR contains
clinical data on all newly diagnosed cancer patients in the
Netherlands. The southern area comprises 2.4 million inhabi-
tants, 10 hospitals, and 2 radiotherapy institutes. After the
initial patient selection, the Patient Reported Outcomes Fol-
lowing Initial Treatment and Long term Evaluation of Survi-
vorship (PROFILES) registry was used for the longitudinal
patient reported data collection [22]. Patients with cognitive
impairments, unverifiable addresses, and patients who died
prior to the study start were excluded from the initial selection.
The remaining CRC patients were invited to participate in
2010 (T1), 2011 (T2), and 2012 (T3). Ethical approval for
the study was obtained from a local certified Medical Ethics
Committee of the Maxima Medical Centre Veldhoven. A
complete overview of the selection process can be found else-
where [17]. The primary objective of this longitudinal study
was to identify the HRQoL and health-care use of long-term
CRC survivors and relate the outcomes to patient and cancer
characteristics. For this secondary analysis, we only included
CRC patients who were less than 5 years after cancer diagno-
sis when they completed their first questionnaire. This cut-off
was chosen as previous research shows that patients change
their lifestyle shortly after cancer diagnosis [23]. Thus, we
expect to see most changes in lifestyle as well as in HRQoL
within 5 years after diagnosis. Moreover, CRC patients with
unknown diabetes status (n=5) or those who developed dia-
betes after completion of the first questionnaire (n=16) were
excluded from this analyses. Data from this longitudinal study
are (partly) available online for noncommercial scientific re-
search, subject to study question, privacy and confidentiality
restrictions, and registration from PROFILES (www.
profilesregistry.nl).
Data collection
CRC patients were invited for participation via the PRO-
FILES registry and a letter from their (ex-) attending specialist
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to inform them of the study. The letter included a secured link
with login and password to the online questionnaire, or pa-
tients could request a paper version of the questionnaire via a
reply card, whichever they preferred. After 2 months, a re-
minder with a paper questionnaire was sent. Patients were
reassured that nonparticipation had no consequences for their
follow-up care or treatment.
Diabetes status, sociodemographic, and clinical
characteristics
Diabetes status was self-reported using the self-administered
comorbidity questionnaire [24]. Patients filled out whether
they had diabetes in the past year or currently. Patients who
reported having diabetes at the first questionnaire were classi-
fied as having diabetes. No distinction wasmade between type
1 and 2 diabetes. Month and year of diabetes diagnosis were
reported only at T2. Similarly, the SCQ was used to assess
comorbidities other than diabetes, including heart disease,
high blood pressure, stroke, lung disease, anemia, kidney dis-
ease, stomach disease, liver disease, thyroid disease, depres-
sion, arthrosis, rheumatoid arthritis, and back pain. Age, gen-
der, and clinical information including cancer diagnosis date,
primary cancer treatment, and cancer stage were derived from
the NCR. Moreover, patients reported their educational level
which was categorized as low (no/primary school), medium
(lower general secondary education/vocational training), or
high (pre-university education/high vocational training/uni-
versity) educational level.
Lifestyle measures
Lifestyle measures were self-reported in the questionnaires
and include smoking, alcohol use, height and weight, and
physical activity. Both smoking and alcohol were assessed
as (1) never, (2) former, and (3) current use. Number of ciga-
rettes smoked per day and glasses of alcohol drunk per week
were also reported. However, as the number of smokers and
current alcohol users among CRCDM+ patients was low (i.e.,
n=13 and n=70 of the 126 included CRCDM+ patients, re-
spectively), no measure of moderate and heavy drinking or
smoking was included. Self-reported body height and weight
were used to calculate BMI. Physical activity was measured
using questions derived from the validated European Prospec-
tive Investigation into Cancer (EPIC) physical activity ques-
tionnaire [25]. Patients filled out howmuch time they spent on
walking, cycling, gardening, household activities and sports,
six different sport types could be specified, during winter and
summer. The mean scores for all activities during winter and
summer were averaged. To assess the intensity, metabolic
equivalent intensity (MET) scores based on previous classifi-
cations were assigned to each activity [26, 27]. Hours per
week spent on moderate to vigorous physical activity
(MVPA) were calculated by summing all activities with a
MET-score ≥3 and include walking (MET=3.5), cycling
(MET=4), gardening (MET=5), and various sports with a
MET-score ≥3. Household activities (MET=3.5) were not
considered as MVPA in accordance with previous research
[28]. To correct for outliers, all activity scores greater than
the 95th percentile were replaced by the 95th percentile.
Health-related quality of life
The validated European Organisation for Research and Treat-
ment of Cancer–Quality of Life Questionnaire (EORTC-
QLQ)-C30 was used to assess HRQoL [29, 30]. As previous
research shows that cancer patients with diabetes mainly score
lower on physical function [7, 10, 11], general HRQoL [6, 9],
and vitality [9] as compared to those without diabetes, and to
prevent type 1 errors as a result of multiple testing, only the
global QoL, physical function, and fatigue scales were includ-
ed in these analyses. All items were answered on a 4-point
Likert scale ranging from ‘not at all’ to ‘very much’, while the
questions regarding global QoL were scored on a 7-point
scale. Item scores were linearly transformed to a 1 to 100
scale. Higher scores on global QoL and physical function
represent better functioning, while a higher score on fatigue
symptoms correspond to more fatigue.
Statistical analyses
Differences in characteristics between respondents and non-
respondents at T1, between patients who completed 1 vs.
those who completed ≥2 questionnaires, and CRCDM+ and
CRCDM− patients of the final study sample were analyzed.
Continuous variables were checked for normality. If variables
were normally distributed, the independent samples t tests
were used. Otherwise, the nonparametric Wilcoxon-Mann-
Whitney test was used to assess differences between the
groups. The chi-square test was used for categorical variables.
First, differences in BMI and MVPA between CRCDM+
and CRCDM− patients at each time point were assessed with
independent samples t tests. Smoking and alcohol status over
time was recoded into one categorical variable with four cat-
egories: persistent smokers/alcohol users, persistent former
smokers/alcohol users, persistent non-smokers/alcohol users,
and patients with fluctuating smoking/alcohol status. Patients
were assigned to the persistent categories when they reported
the same category on all questionnaires; otherwise, they were
included in the fluctuating status category. Differences in
smoking and alcohol category between CRCDM+ and
CRCDM− patients were assessed with chi-square tests.
In order to gain insight into the differences in HRQoL
between CRCDM+ and CRCDM− patients with different life-
style behaviors, we reported unadjusted means of physical
function, global QoL, and fatigue stratified by diabetes status
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for each lifestyle factor measured at T1. To adjust for the
dependence of observations within subjects, generalized line-
ar mixed models, using an unstructured covariance structure,
were constructed. First, differences in lifestyle factors between
CRCDM+ and CRCDM− patients over time were assessed in
a model that included the main effects of DM, time, and the
interaction between DM and time. When the interaction term
was significant, the results for CRCDM+ and CRCDM− pa-
tients were stratified; otherwise, the interaction term was re-
moved from the model in order to interpret the main effects of
DM and time. Second, similar general linear mixed models
were used to assess the main effects of DM and time on global
QoL, physical function, and fatigue. Both models that ad-
dressed differences in lifestyle and HRQoL were adjusted
for sociodemographic (age, sex, educational level) and clinical
characteristics (time since cancer diagnosis, cancer stage, and
treatment). Finally, the models predicting HRQoL were addi-
tionally adjusted for lifestyle factors to assess whether differ-
ences in HRQoL between CRCDM+ and CRCDM− could be
explained by lifestyle. To examine the independent between
and within-subject effects of BMI andMVPA onHRQoL, two
terms were included in the model; a between term, represented
by a person’s average BMI or MVPA over the two or three
time points, as well as a within term, represented by the dif-
ference between a person’s BMI or MVPA at one time point
and that persons average BMI or MVPA over the two or three
time points. The categorical variables (i.e., persistent and fluc-
tuating use) for both smoking and alcohol use were included
in the generalized linear mixed models. The continuous vari-
ables (i.e., age and time since cancer diagnosis) were grand-
mean centered in order to correctly interpret all model param-
eters. Moreover, as we expect that cancer patients with
diabetes have more comorbid conditions other than diabetes
and as comorbidity has previously been shown to impact on
HRQoL among cancer patients [31], we conducted a sensitiv-
ity analyses to see whether comorbidity other than diabetes
explains the differences in HRQoL (i.e., beyond lifestyle fac-
tors) between CRCDM+ and CRCDM− patients. As infor-
mation on the duration of diabetes at the study start was
available for a subsample, we assessed whether there were
differences between CRCDM+ with a diabetes duration
<6.5 years and ≥6.5 years vs. CRCDM− patients in a
sub-analysis. This cut-off was based on the median diabe-
tes duration.
A p value <0.05 was regarded as statistically significant
and all analyses were conducted using SAS statistics version
9.3 (SAS Institute, Inc., Cary, NC).
Results
Patient selection process
Of the 3585 eligible CRC patients, 2625 (73 %) responded to
the first questionnaire and 1739 (49 %) responded to ≥2 ques-
tionnaires. After excluding patients who were ≥5 years after
cancer diagnosis, patients with an unknown diabetes status
(n=5, 1 %) and those who developed diabetes during the
study period (n=16, 2 %), 126 CRCDM+ and 789 CRCDM
− patients were included (Fig. 1). Full details of the studies
selection process can be found online at http://www.
profilesregistry.nl/dataarchive/study_units/view/22 under
‘Data & Documentation’. More details of the study process,







Response on T≥2: N=1,739 
(49%)
<5 years after CRC dx:
N=936 (54%)
N=16 (2%) developed diabetes 
during the study
N=5 (1%) diabetes status 
unknown
915 CRC patients included:
- N=789 (84%) without diabetes
- N=126 (13%) with diabetes
Fig. 1 Flowchart of the study
process
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comparison of those who completed 1 vs. ≥2 questionnaires
are reported elsewhere [17]. In general, respondents at T1
were significantly younger, more often male, and more often
diagnosed with stage I disease than non-respondents. CRC
patients who completed ≥2 vs. only 1 questionnaire were
younger (68.4 ± 9.4 vs. 71.3 ± 9.4 years), less often female
(43 vs. 49 %), and less often diagnosed with stage IV
disease (3 vs. 7 %). Moreover, CRC patients who completed
≥2 vs. 1 questionnaire were more likely to consume alcohol
(73 vs. 61 %), were more physically active (12±9 vs. 9±9 h/
week spent on MVPA), and reported a higher global QoL (79
±18 vs. 73±21), higher physical function (82±19 vs. 75±
23), and lower fatigue levels (20±22 vs. 26±26).
Differences in characteristics and lifestyle factors
over time between CRCDM+ and CRCDM−
CRCDM+ patients were lower educated (24 vs. 14 % with a
low education) and had more comorbid conditions other
than diabetes (50 vs. 35 % with ≥2 comorbid conditions
other than diabetes, Table 1). Diabetes duration was avail-
able for 95 (75 %) CRCDM+ patients and CRCDM+ pa-
tients were diagnosed with diabetes on average 8.3
±7.2 years prior to the study start. No differences between
CRCDM+ and CRCDM− patients were found on sex, age,
cancer stage, time since cancer diagnosis, and cancer
treatment.
CRCDM+ patients had a significantly higher BMI at T1
(29.1 ± 4.2 vs. 26.4 ± 3.7 kg/m2), T2 (28.6 ± 4.3 vs. 26.5
± 4.4 kg/m2), and T3 (29.1 ± 4.1 vs. 26.4 ± 3.9 kg/m2, all
p values <0.0001, Fig. 2a). In adjusted generalized linear
mixed models, no interaction of DM*time was found, in-
dicating that BMI did not differ between both groups over
time. After removing the interaction term, a main effect for
diabetes (beta = 2.44; SE= 0.35, p value <0.0001) but not
for time (p value = 0.06) on BMI was observed. No differ-
ence between CRCDM+ and CRCDM− in MVPA at T1 (p
value = 0.07), T2 (p value = 0.27), or T3 (p value = 0.59)
was observed (Fig. 2b). Again, no interaction between
DM and time was observed, indicating that MVPA did
not differ between both groups over time. No main effect
of DM was observed while MVPA did significantly change
over time (p value = 0.01). Although, there were slightly
more CRCDM+ patients who persistently reported to be
ex-smokers (63 vs. 53 %), no overall difference in smoking
status between CRCDM+ and CRCDM− was observed (p
value = 0.09). However, among CRCDM+, there were few-
er patients who persistently reported to use alcohol (50 vs.
70 %, p value <0.0001). Both smoking and alcohol status
were quite stable over time with 8 % (n= 77) and 13 %
(n= 126) reporting fluctuating smoking and alcohol status
during the study period, respectively.
Differences in HRQoL and the impact of lifestyle
on HRQoL among CRCDM+ and CRCDM− patients
Physical function was lowest among CRCDM+ patients with
BMI ≥30 kg/m2 (mean at T1 68±23) and highest among CRC
patients with BMI between 25–30 kg/m2 (at T1: both
CRCDM− and CRCDM+ 84±18, Fig. 3). CRCDM− patients
with ≥14 h/weekMVPA reported highest physical function (at
T1 89±14), whereas inactive CRC patients report the lowest
physical function (at T1, CRCDM− 59±24 and CRCDM+
patients 58±26). CRCDM− and CRCDM+ patients who nev-
er smoked reported highest physical function (at T1 84±16
and 76 ± 19, respectively), while smokers reported lowest
Table 1 Sociodemographic and clinical characteristics (T1) of the
study population
n (%) or mean ± SD CRCDM+ CRCDM−
n= 126 n= 789 p value
Male 80 (63) 453 (57) 0.2
Age (years) 70 ± 8 68± 10 0.06b
Educational levela
Low 30 (24) 113 (14) 0.02
Medium 73 (58) 488 (62)
High 23 (18) 184 (23)
Comorbidity other than diabetes
0 20 (16) 241 (32) 0.0006
1 42 (34) 251 (33)
≥2 61 (50) 263 (35)
Cancer stage
I 38 (30) 218 (28) 0.40
II 41 (33) 264 (33)
III 41 (33) 236 (30)
IV 5 (4) 38 (5)
Unknown 1 (1) 33 (4)
Time since diagnosis (years) 3 ± 1 3 ± 1 0.16b
Surgery 124 (98) 785 (99) N/A
Chemotherapy 46 (37) 258 (33) 0.40
Radiotherapy 36 (29) 262 (33) 0.3
Diabetes duration (years) 8.3 ± 7.2
Diabetes duration—categorical
<6.5 years 47 (37)
≥6.5 years 48 (38)
Unknown 31 (24)
N/A no valid p value could be obtained as the number of patients who did
not receive surgery was too low (i.e., 2 CRCDM+ and 4 CRCDM−
patients) to conduct a valid chi-square test
a Education levels included the following categories: low= no/primary
school, medium= lower general secondary education/vocational training,
or high = pre-university education/high vocational training/university
b Statistical difference tested with the nonparametric Wilcoxon-Mann-
Whitney test
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physical function with 78±19 and 62±32, respectively. Al-
cohol users reported higher physical function as compared to
former or never users. For global QoL and fatigue, similar
patterns were observed. In general, smokers, obese patients
(BMI ≥30 kg/m2) and inactive patients reported lowest QoL
and most fatigue, while alcohol drinkers reported highest
global QoL and lowest fatigue (data not shown).
In adjusted generalized linear mixed models, no interaction
effect between DM and time was found on any of the HRQoL
scales, meaning that HRQoL did not differ between CRCDM+
and CRCDM− patients over time. After removing the interac-
tion term, CRCDM+ patients reported significantly lower
physical function (beta=−5.76; SE=1.67), global QoL (be-
ta = −4.31; SE = 1.48), and more fatigue (beta = 5.38;
SE=1.95) than CRCDM− patients. However, after additional
adjustments for BMI, MVPA, smoking, and alcohol use the
main effect of diabetes disappeared for all three subscales
(Table 2, model 2). With each point increase in BMI, physical
function decreased (beta= -0.71; SE 0.15), and symptoms of
fatigue increased (beta=0.47; SE=0.18). No within-subject
effect of BMI was found, i.e., individual changes in BMI dur-
ing the study period were not associated with changes in
HRQoL.With each hour increase inMVPA per week, physical
function (beta=0.64; SE=0.07) and global QoL increased (be-
ta=0.35; SE=0.07) whereas symptoms of fatigue decreased
(beta=−0.50; SE=0.09). Awithin-subject effect was found for
both physical function and fatigue indicating that when a
person increased their MVPA with 1 h per week above their
averageMVPA during the study period, their physical function
increased with 0.09 points (SE=0.04) and their fatigue score
decreased with 0.15 (SE=0.06). Persistent smoking as com-
pared to never smoking was associated with lower physical
function and global QoL and more fatigue. In contrast, persis-
tent drinking during the study period was associated with
higher physical function and global QoL and less fatigue.
After additionally adjusting the full model 2 for comor-
bidity (i.e., 1 or ≥2 vs. 0 comorbidity), the main effect of
diabetes was attenuated even further for physical function
(beta DM+ vs. DM−=−0.85, SE=1.56), global QoL (beta
DM+ vs. DM−=−1.43, SE=1.48), and fatigue (beta DM+
vs. DM−=1.11, SE=0.56). All lifestyle factors remained
independently associated with HRQoL and estimates were
similar to those presented in model 2, Table 2.
We also included diabetes duration and used a categorical
variable including CRCDM−, CRCDM+ with <6.5 years di-
abetes duration, CRCDM+ with ≥6.5 years diabetes duration
and CRCDM+ with unknown diabetes duration in the model.
We found that in model 1 CRCDM+ with short diabetes du-
ration (i.e., <6.5 years) was associated with worse global QoL
(beta= -5.02, SE=2.32) while longer term diabetes duration
(i.e., ≥6.5 years) was associated with lower physical function
(beta=−6.56, SE=2.56, data not shown). After adjustment
















































































a BMI b MVPA
c Smoking d Alcohol
Fig. 2 Differences in a BMI,
bMVPA, c Smoking, and
d alcohol use between CRCDM−
( ) and CRCDM+( ).
**Significant difference
between CRCDM+ and CRCDM
− using independent samples t test
with p value <0.0001. BMI body
mass index, MVPA moderate-to-
vigorous physical activity
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Discussion
This study shows that CRCDM+ and CRCDM− differed re-
garding lifestyle behaviors; CRCDM+ had a higher BMI and
was less likely to consume alcohol. No differences in MVPA
and smoking status between CRCDM+ and CRCDM− pa-
tients were observed. In addition, prospectively measured
physical function and global QoL were lower, while fatigue
was higher among CRCDM+ patients as compared to
CRCDM− patients. However, these differences in HRQoL
outcomes disappeared after adjusting for lifestyle factors;
BMI, MVPA, smoking, and alcohol were all significant pre-
dictors of HRQoL. Further adjustment for comorbidity further
attenuated the main effect of diabetes. This suggests that dia-
betes is not independently associated with HRQoL but that the
found lower HRQoL scores among CRCDM+ patients seem
to be explained by an unhealthier lifestyle and other comorbid
conditions.
A few studies assessedHRQoL among cancer patients with
and without diabetes and adjusted for lifestyle factors; two
studies adjusted for BMI only [8, 10] and one study adjusted
for BMI, physical activity, and smoking [6]. In line with our
results, all three studies reported higher BMI among cancer
patients with vs. without DM. Moreover, a large Canadian
cross-sectional study (n=113,587) also reported lower phys-
ical activity (14 vs. 20% being active) and no clear differences
in the frequency of smoking (18 vs. 16 %) between both
groups [6]. In contrast to our results, after adjustment for
BMI (and smoking), all three studies reported a lower HRQoL
among cancer patients with vs. without diabetes [6, 8, 10]. The
large Canadian cross-sectional study found a lower Health
Utility Index-3 score among cancer patients with vs. without
DM with beta=−0.04 (95 % CI −0.05;−0.03) [6]. A longitu-
dinal study among prostate cancer patients (n=1248) reported
a lower urinary function among prostate cancer patients with
vs. without diabetes, while no differences were found on other
urinary and sexual function subscales [8]. In our previous
cross-sectional study, we observed a lower physical function
(beta =−3.8) and more male sexual problems (beta = 9.4)
among CRCDM+ vs. CRCDM− patients [10]. The different
cancer types studied and the different measurements used in
previous studies hamper comparison of the results. This study
shows that besides BMI and smoking, MVPA and alcohol use
were also independently associated with HRQoL and should
be taken into account when comparing HRQoL between can-
cer patients with and without diabetes. Only adjusting for BMI
might not be sufficient. Alcohol consumption was associated













DM- MVPA, ≥14 hrs/wk, n=263
DM-  MVPA, 7-14 hrs/wk, n=272
DM-  MVPA, 1-7 hrs/wk, n=227
DM-  MVPA, 0 hrs/wk, n=26
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DM-  Never smoked, n=258
DM-  Former smokers, n=443
DM-  Smokers, n=87
DM+ Never smoked, n=29
DM+ Former smokers, n=84












DM-  Never used alcohol, n=148
DM-  Former alcohol users, n=42
DM-  Currently using alcohol, n=593
DM+ Never used alcohol, n=40
DM+ Former alcohol users, n=15
DM+ Currently using alcohol, n=70
a Physical functioning by BMI and diabetes status b Physical functioning by MVPA and diabetes status
c Physical functioning by smoking and diabetes status d Physical functioning by alcohol and diabetes status
Fig. 3 Mean scores on physical function stratified by BMI and lifestyle
factors (measured at T1) and diabetes status. a Physical functioning by
BMI and diabetes status. b Physical functioning by MVPA and diabetes
status. c Physical functioning by smoking and diabetes status. d Physical
functioning by alcohol and diabetes status
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[13]. We assume that the alcohol users in our study consumed
moderate amounts which may be associated with fewer co-
morbid conditions such as cardiovascular disease. Vice versa
patients with severe chronic disease might consume less alco-
hol. The results of the present study emphasize that health
professionals still need to encourage and support cancer pa-
tients in improving their lifestyle behaviors. Besides, provid-
ing adequate information on behavior change, health profes-
sionals also have to consider attitudes and motivations [32].
In this study, no information on clinical data regarding
diabetes diagnosis was available. However, we did have in-
formation regarding self-reported diabetes duration for 75 %
of the CRCDM+ patients. One might expect that patients with
a longer diabetes duration develop more complications which
in turn lead to lower HRQoL.We showed that CRCDM+with
a diabetes duration <6.5 years had lower global QoL while
CRCDM+ patients with a diabetes duration ≥6.5 years had a
lower physical function as compared to CRCDM− patients.
These differences were attenuated after adjustments for co-
morbidity and lifestyle, similar as in the main analyses. The
absence of a consistent pattern might be due to the stratifica-
tion which resulted in a low number of patients per group.
As cardiovascular diseases and kidney diseases are com-
mon among patients with diabetes [33] and comorbidity is
significantly associated with HRQoL [31], we additionally
adjusted model 2 for comorbidity in a sensitivity analysis.
We initially did not adjust for comorbidity as adjustment for
both lifestyle factors and comorbidity might lead to an
overadjusted model. From literature, we know that impaired
glucose tolerance, insulin resistance, obesity, dyslipidemia,
and hypertension co-occur more often than might expected
by chance [34]. This group of risk factors is also known as
the Metabolic syndrome [34]. Thus, the metabolic syndrome
might be part of the causal pathway for the development of
diabetes. As we had no information on the date of diagnosis of
the other comorbid conditions, we cannot ascertain whether
Table 2 The results of generalized linear mixed models to assess the effect of diabetes and lifestyle factors on physical function, global quality of life,
and fatigue
Physical function Global quality of life Fatigue
Model 1 Model 2 Model 1 Model 2 Model 1 Model 2
beta (se) beta (se) beta (se) beta (se) beta (se) beta (se)
DM+ vs. DM− −5.76 (1.67)* −2.12 (1.61) −4.31 (1.48)* −2.66 (1.53) 5.38 (1.95)* 2.26 (1.95)
Time
T2 vs. T1 −0.95 (0.71) −0.69 (0.70) −2.67 (0.75)* −2.12 (0.75)* 1.53 (0.92) 1.20 (0.92)
T3 vs. T1 −2.29 (1.25) −1.82 (1.19) −2.51 (1.21)* −2.60 (1.21)* 2.30 (1.55) 1.67 (1.52)
BMI (kg/m2)
Betweena −0.71 (0.15)** −0.24 (0.14) 0.47 (0.18)*
Withinb 0.06 (0.12) −0.03 (0.15) 0.22 (0.17)
MVPA (h/week)
Betweena 0.64 (0.07)** 0.35 (0.07)** −0.50 (0.09)**
Withinb 0.09 (0.04)* 0.05 (0.05) −0.15 (0.06)*
Smoking
Persistent former vs. never −3.98 (1.34)* −2.88 (1.27)* 2.66 (1.63)
Persistent current vs. never −10.24 (2.06)** −5.52 (1.95)* 8.21 (2.50)*
Fluctuating vs. persistent never −5.55 (2.16)* −3.01 (2.06) 4.61 (2.63)
Alcohol
Persistent former vs. never −4.27 (3.59) −0.98 (3.40) 0.20 (4.36)
Persistent current vs. never 5.97 (1.68)* 3.98 (1.60)* −7.01 (2.06)*
Fluctuating vs. persistent never 3.72 (2.05) 0.74 (1.95) −3.10 (2.49)
Model 1: Model to assess main effects of diabetes and time on HRQoL adjusted for age, sex, time since cancer diagnosis, cancer stage (stage I, II, III vs.
stage IV), cancer treatment (radiotherapy: yes/no and chemotherapy: yes/no), and educational level (medium and high vs. low educational level)
Model 2: Model 1 with additional adjustments for lifestyle factors
BMI body mass index, MVPA moderate-to-vigorous physical activity
*p value <0.05
**p value <0.0001
a Between-subjects effects represented by the persons average over all time points
bWithin-subjects effects represented by the difference between the average at one time point and the persons average over all time points
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these conditions developed after, and possibly as a result of,
diabetes.
Obesity, physical inactivity, smoking, and alcohol use are
all risk factors for both CRC and diabetes [35]. Although these
lifestyle factors might have influenced the development of
both diabetes and cancer among patients in this study, our
results show that changes in lifestyle habits can improve
HRQoL after the diagnosis of both diseases: patients who
increased their physical activity during the study period re-
ported higher physical function and less symptoms of fatigue.
Among cancer survivors, several lifestyle interventions fo-
cused on improving dietary habits, smoking cessation, or in-
creasing physical activity show promising results [23]. More-
over, in recent years, interventions have also focused on in-
creasing physical and emotional condition prior to cancer
treatment [36]. These prehabilitation studies showed promis-
ing results regarding morbidity, mortality, length of hospital
stay, and HRQoL [36]. However, sustainable long-term ef-
fects of these lifestyle and prehabilitation interventions are
rarely studied. Thus, future studies should focus on the devel-
opment of prehabilitation and lifestyle interventions that are
effective on the long term.
This study has several limitations. First, no information
regarding lifestyle and HRQoL prior to cancer diagnosis were
available. As data were collected 1 to 5 years after cancer
diagnosis, patients might have adopted their lifestyle directly
after diagnosis and prior to the data collection which could
have influenced our results. In addition, no information re-
garding diet was available. Moreover, lifestyle factors were
self-reported and may have been influenced by recall bias
and social desirability. Previous research shows high correla-
tions between self-reported and objectively assessed BMI;
however, elderly (>60 years) often overreport their height
and as a result, BMI is underreported [37]. In addition, the
patients included in these analyses are likely to be healthier
as those with poorer health are less likely to participate in the
study and to complete the follow-up questionnaires. As a re-
sult, absolute scores on HRQoL should be interpreted cau-
tiously. However, we do not expect the found association to
be different as patients who did not respond or completed the
follow-up are likely to report both poorer lifestyle behaviors
and poorer HRQoL. Moreover, no data regarding diabetes
type (i.e., type 1 or type 2), severity, and complications were
available, although we did conduct a sub-analysis including
diabetes duration and additionally adjusted for comorbidity.
Finally, diabetes was self-reported which could have resulted
in misclassification. Despite these limitations, this population-
based study with relatively high response is the first to pro-
spectively address differences in HRQoL between CRCDM+
and CRCDM− patients and the impact of lifestyle.
In conclusion, this study showed that CRCDM+ patients
reported lower prospectively measured HRQoL as compared
to CRCDM− patients; however, these differences disappeared
after adjustments for lifestyle and other comorbidities. These
results suggest that lifestyle factors and comorbidity might
explain the difference in HRQoL between CRCM+ and
CRCDM− patients, although residual confounding cannot be
excluded. As BMI, MVPA, smoking, and alcohol use were all
independently associated with HRQoL, this study underlines
the importance of improving lifestyle behaviors among CRC
patients, either with or without diabetes.
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